The effectiveness of vaccines got here to the fore at a time when circumstances from the delta variant had been on the rise worldwide.
Germany-based biotechnology firm BioNTech made an announcement on the topic.
Within the assertion, “There isn’t a need yet to adapt the BioNTech-Pfizer vaccine for coronavirus variants.” it was mentioned.
Uğur Şahin, Chairman of BioNTech’s Board of Administrators, said that the coronavirus vaccine produced by his firms is efficient in opposition to variants, “There’s at present no proof that adapting our vaccine to current variants is important.” he had spoken.
#BioNTech #adapt #coronavirus #vaccine #variants
Dikkat: Sitemiz herkese açık bir platform olduğundan, çox fazla kişi paylaşım yapmaktadır. Sitenizden izinsiz paylaşım yapılması durumunda iletişim bölümünden bildirmeniz yeterlidir.